Table 4.
Intention-to-treat analysis of changes in prescribing rates showing sum scores per clinical topic and scores per drug
| Intervention | Control | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical topic | n | Mean before (sd) | Mean after (sd) | n | Mean before (sd) | Mean after (sd) | Ba (95% CI) | icc | Direction | p |
| Anaemia | ||||||||||
| Iron preparations, oral | 39 | 25.0 (20.7) | 45.1 (40.0) | 49 | 27.4 (28.4) | 49.2 (55.7) | 3.9 (−13.9, 21.5) | 0.21 | = | 0.644 |
| Urinary tract infections | ||||||||||
| Antibiotics UTI | 39 | 43.5 (31.6) | 47.3 (36.5) | 49 | 47.5 (38.7) | 59.7 (48.7) | 11.9 (−3.2, 27.0) | 0.21 | ↓ | 0.113 |
| Prostate complaints | 39 | 59.1 (43.3) | 107.1 (69.6) | 49 | 66.5 (58.6) | 127.5 (102.2) | 20.0 (−20.9, 60.8) | 0.38 | ↓ | 0.306 |
| Alpha receptor blockers | 39 | 49.6 (35.7) | 86.6 (56.2) | 49 | 55.0 (49.5) | 103.3 (81.5) | 18.5 (−15.3, 52.3) | 0.42 | ↓ | 0.258 |
| 5 alpha reductase inhibitors | 39 | 9.5 (9.5) | 20.4 (18.6) | 49 | 11.5 (11.2) | 24.2 (24.7) | 1.4 (−7.2, 10.0) | 0.01 | ↓ | 0.735 |
| Stomach complaints | 49 | 329.7 (286.9) | 612.0 (477.0) | 39 | 282.6 (210.1) | 491.8 (333.4) | 106.7 (−70.7, 284.2) | 0.63 | ↓ | 0.219 |
| H2 antagonists | 49 | 27.8 (26.4) | 32.4 (30.0) | 39 | 22.3 (20.5) | 21.3 (16.4) | 12.5 (−1.8, 26.8) | 0.44 | ↑ | 0.081 |
| Proton pump inhibitors | 49 | 300.8 (262.9) | 578.3 (452.3) | 39 | 259.4 (192.3) | 469.1 (322.1) | 93.7 (−71.9, 259.4) | 0.62 | ↓ | 0.246 |
| Misoprostol | 49 | 0.1 (0.4) | 0.0 (0.2) | 39 | 0.1 (0.4) | 0.2 (0.5) | −0.1 (−0.2,−0.0) | 0.00 | ↓ | 0.008 b |
| Triple therapy (ATC A02BD04) | 49 | 1.0 (1.7) | 1.3 (2.0) | 39 | 0.9 (1.3) | 1.1 (1.7) | 0.2 (−0.7, 1.2) | 0.49 | ↓ | 0.593 b |
| Thyroid dysfunction | 49 | 81.3 (66.3) | 137.2 (102.6) | 39 | 71.4 (48.9) | 107.1 (71.6) | 21.2 (−14.1, 56.6) | 0.42 | = | 0.217 |
| Thyroid hormones | 49 | 74.8 (60.8) | 125.0 (92.6) | 39 | 66.9 (47.4) | 100.8 (70.0) | 18.2 (−16.0, 52.4) | 0.45 | = | 0.269 |
| Antithyroid preparations | 49 | 6.5 (8.6) | 12.2 (17.8) | 39 | 4.5 (4.4) | 6.3 (7.3) | 2.6 (−1.7, 7.0) | 0.09 | ↑ | 0.218 b |
| Perimenopausal complaints | 49 | 56.4 (42.7) | 56.8 (41.8) | 39 | 46.3 (34.2) | 46.0 (29.6) | 6.6 (−12.0, 25.2) | 0.56 | ↓ | 0.459 |
| Oestrogens, oral | 49 | 14.1 (13.6) | 12.7 (12.1) | 39 | 12.3 (11.8) | 11.2 (10.4) | 0.2 (−3.6, 4.1) | 0.01 | ↓ | 0.889 |
| Contraceptives (>50y) | 49 | 3.6 (3.2) | 6.4 (4.9) | 39 | 3.2 (3.9) | 5.9 (4.2) | 1.1 (−1.9, 4.2) | 0.34 | ↓ | 0.431 |
| Hormone replacement therapy | 49 | 34.8 (28.6) | 34.7 (27.0) | 39 | 28.3 (19.7) | 26.3 (17.8) | 5.8 (−6.5, 18.0) | 0.70 | ↓ | 0.331 |
| Clonidine | 49 | 0.5 (1.8) | 0.5 (2.0) | 39 | 0.2 (0.5) | 0.4 (2.0) | 0.1 (−1.0, 1.2) | 0.13 | ↓ | 0.908 b |
| Tibolon | 49 | 3.4 (4.1) | 2.4 (2.7) | 39 | 2.3 (2.8) | 2.2 (3.4) | −0.3 (−1.4, 0.8) | 0.00 | ↓ | 0.615 |
The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
n = number of practices
aAdjusted difference between groups at end of intervention, corrected for baseline
bstatistically significant interaction
Misoprostol
P 10: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
P 90: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
Triple therapy (ATC A02BD04)
P10: B (95% CI): 0.9 (−0.2, 1.9). p: 0.117
P90: B (95% CI):−0.4 (−1.6, 0.7). p: 0.413
Antithyroid preparations
P10: B (95% CI):−1.9 (−7.2, 3.4). p: 0.474
P90: B (95% CI): 12.3 (4.6, 19.9). p: 0.002
Clonidine
P10: B (95% CI): 0.6 (−0.4, 1.6). p: 0.215
P90: B (95% CI):−2.4 (−3.9,−1.0). p: < 0.001